chr14-50905380-CA-C

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP6_Very_StrongBA1

The NM_002863.5(PYGL):​c.*11delT variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.36 ( 10889 hom., cov: 0)
Exomes 𝑓: 0.30 ( 73702 hom. )

Consequence

PYGL
NM_002863.5 3_prime_UTR

Scores

Not classified

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 0.00

Publications

8 publications found
Variant links:
Genes affected
PYGL (HGNC:9725): (glycogen phosphorylase L) This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1,4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Feb 2011]
PYGL Gene-Disease associations (from GenCC):
  • glycogen storage disease VI
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia, Genomics England PanelApp, Orphanet, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP6
Variant 14-50905380-CA-C is Benign according to our data. Variant chr14-50905380-CA-C is described in ClinVar as Benign. ClinVar VariationId is 258828.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.59 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PYGLNM_002863.5 linkc.*11delT 3_prime_UTR_variant Exon 20 of 20 ENST00000216392.8 NP_002854.3
PYGLNM_001163940.2 linkc.*11delT 3_prime_UTR_variant Exon 19 of 19 NP_001157412.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PYGLENST00000216392.8 linkc.*11delT 3_prime_UTR_variant Exon 20 of 20 1 NM_002863.5 ENSP00000216392.7
PYGLENST00000532462.5 linkc.2379+2890delT intron_variant Intron 19 of 19 1 ENSP00000431657.1
PYGLENST00000544180.6 linkc.*11delT 3_prime_UTR_variant Exon 19 of 19 2 ENSP00000443787.1

Frequencies

GnomAD3 genomes
AF:
0.361
AC:
54825
AN:
151826
Hom.:
10854
Cov.:
0
show subpopulations
Gnomad AFR
AF:
0.458
Gnomad AMI
AF:
0.115
Gnomad AMR
AF:
0.481
Gnomad ASJ
AF:
0.242
Gnomad EAS
AF:
0.608
Gnomad SAS
AF:
0.366
Gnomad FIN
AF:
0.304
Gnomad MID
AF:
0.426
Gnomad NFE
AF:
0.273
Gnomad OTH
AF:
0.376
GnomAD2 exomes
AF:
0.371
AC:
93051
AN:
251102
AF XY:
0.357
show subpopulations
Gnomad AFR exome
AF:
0.457
Gnomad AMR exome
AF:
0.622
Gnomad ASJ exome
AF:
0.244
Gnomad EAS exome
AF:
0.603
Gnomad FIN exome
AF:
0.306
Gnomad NFE exome
AF:
0.273
Gnomad OTH exome
AF:
0.336
GnomAD4 exome
AF:
0.304
AC:
441245
AN:
1449560
Hom.:
73702
Cov.:
0
AF XY:
0.304
AC XY:
219596
AN XY:
721956
show subpopulations
African (AFR)
AF:
0.469
AC:
15578
AN:
33182
American (AMR)
AF:
0.605
AC:
27039
AN:
44676
Ashkenazi Jewish (ASJ)
AF:
0.254
AC:
6617
AN:
26040
East Asian (EAS)
AF:
0.627
AC:
24835
AN:
39606
South Asian (SAS)
AF:
0.354
AC:
30407
AN:
85962
European-Finnish (FIN)
AF:
0.301
AC:
16071
AN:
53380
Middle Eastern (MID)
AF:
0.380
AC:
2178
AN:
5734
European-Non Finnish (NFE)
AF:
0.271
AC:
298723
AN:
1101016
Other (OTH)
AF:
0.330
AC:
19797
AN:
59964
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.456
Heterozygous variant carriers
0
13258
26516
39775
53033
66291
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10282
20564
30846
41128
51410
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.361
AC:
54906
AN:
151944
Hom.:
10889
Cov.:
0
AF XY:
0.367
AC XY:
27278
AN XY:
74258
show subpopulations
African (AFR)
AF:
0.459
AC:
19016
AN:
41454
American (AMR)
AF:
0.482
AC:
7353
AN:
15256
Ashkenazi Jewish (ASJ)
AF:
0.242
AC:
837
AN:
3462
East Asian (EAS)
AF:
0.607
AC:
3133
AN:
5158
South Asian (SAS)
AF:
0.366
AC:
1760
AN:
4814
European-Finnish (FIN)
AF:
0.304
AC:
3202
AN:
10532
Middle Eastern (MID)
AF:
0.428
AC:
124
AN:
290
European-Non Finnish (NFE)
AF:
0.273
AC:
18582
AN:
67954
Other (OTH)
AF:
0.376
AC:
794
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1699
3398
5098
6797
8496
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
524
1048
1572
2096
2620
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.309
Hom.:
1394
Bravo
AF:
0.384
Asia WGS
AF:
0.489
AC:
1699
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 10, 2016
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Oct 26, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

May 14, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Glycogen storage disease, type VI Benign:2
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 07, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
0.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3216001; hg19: chr14-51372098; COSMIC: COSV53587647; COSMIC: COSV53587647; API